We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

79 hedge funds and large institutions have $143M invested in Stemline Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

23% more capital invested

Capital invested by funds: $116M → $143M (+$27M)

13% more funds holding

Funds holding: 70 → 79 (+9)

13% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 23

28% less call options, than puts

Call options by funds: $1.22M | Put options by funds: $1.7M

Holders
79
Holders Change
+9
Holders Change %
+12.86%
% of All Funds
1.97%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
20
Reduced
23
Closed
4
Calls
$1.22M
Puts
$1.7M
Net Calls
-$476K
Net Calls Change
-$1.65M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.18M
2
LSC
Lyon Street Capital
California
+$3.91M
3
CWG
C WorldWide Group
Denmark
+$1.5M
4
CCM
Consonance Capital Management
New York
+$954K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$929K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.05M
2
Millennium Management
Millennium Management
New York
-$2.91M
3
IBT
International Biotechnology Trust
United Kingdom
-$2.54M
4
SM
Sabby Management
Florida
-$1.35M
5
CCI
Columbus Circle Investors
-$523K
Name Holding Trade Value Shares
Change 		Change in
Stake
B
26
Bailard
California
$717K -$180K -19,185 -23%
PVI
27
Pura Vida Investments
New York
$666K – – –
TCIM
28
TIAA CREF Investment Management
New York
$598K -$29.7K -3,162 -6%
Ameriprise
29
Ameriprise
Minnesota
$487K +$56.4K +6,000 +16%
SM
30
Sabby Management
Florida
$486K -$1.35M -143,751 -77%
TA
31
Teachers Advisors
New York
$482K – – –
Charles Schwab
32
Charles Schwab
California
$447K – – –
CI
33
Cowen Inc
New York
$420K +$355K +37,800 New
Goldman Sachs
34
Goldman Sachs
New York
$415K +$352K +37,422 New
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$398K -$39.8K -4,233 -11%
ELI
36
Empire Life Investments
Ontario, Canada
$373K +$316K +33,613 New
Millennium Management
37
Millennium Management
New York
$370K -$2.91M -309,206 -90%
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$345K – – –
Morgan Stanley
39
Morgan Stanley
New York
$336K -$21K -2,235 -7%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$307K +$2.73K +290 +1%
CD
41
Carl Domino
Florida
$289K – – –
PAM
42
Panagora Asset Management
Massachusetts
$289K – – –
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$288K +$244K +25,914 New
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$216K +$2.07K +220 +1%
AllianceBernstein
45
AllianceBernstein
Tennessee
$214K – – –
AQR Capital Management
46
AQR Capital Management
Connecticut
$212K -$61K -6,488 -25%
TI
47
Telemetry Investments
New York
$205K -$61.1K -6,500 -26%
Barclays
48
Barclays
United Kingdom
$204K +$158K +16,793 +1,039%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$202K – – –
Balyasny Asset Management
50
Balyasny Asset Management
Illinois
$193K +$164K +17,400 New
1
2
3 4

STML Hedge Fund Activity: Q3 2017 in Review

79 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2017, worth a combined $143M — up 23% from $116M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new STML positions and 4 closed out — a net gain of 9 holders — while 20 added to existing stakes and 23 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $6.18M. The largest seller was Fidelity Investments, cutting an estimated $5.05M.

  • 79 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2017, up from 70 in Q2 2017.
  • Funds reported $143M of Stemline Therapeutics, Inc. stock for Q3 2017, up 23% quarter-over-quarter.
  • 13 funds opened new Stemline Therapeutics, Inc. positions in Q3 2017 and 4 closed out, a net change of +9 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q3 2017 was Adage Capital Partners, an estimated $6.18M added.
  • The largest Stemline Therapeutics, Inc. seller in Q3 2017 was Fidelity Investments, an estimated $5.05M sold.

Based on aggregated 13F filings for Q3 2017.